National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group

Recruiting

• Conditions: Sarcoma

• Registration Number: NCT03978039
• Lead Sponsor: Institut Bergonié

Brief Summary

The BCB SARCOMES database is a clinical and biological national database dedicated to sarcoma that contains 3 main databases with specific aims: the first is the pathology database (French expert network dedicated to the management of bone sarcomas \[RESOS\] / French expert network dedicated to the pathology of sarcomas \[RREPS\]), dedicated to systematic review of mesenchymal tumor diagnostics nationwide; the second is clinical (RESOS / French expert clinical network for sarcomas \[NETSARC\]), collecting multidisciplinary tumor boards (MDTB) data of patients nationwide, and the third (CONTICABASE / BONE / GIST) is dedicated to collecting patients longitudinal/follow up data, with a focus on treatments of every events, and a catalogue of associated samples.

Primary objectives of BCB-SARCOMES are the following: description of the patterns of care and treatment outcomes, assessment of the prognostic factors of patients' outcomes.

With the financial support of the French National Cancer Institute \[Institut National du cancer \[INCa\]).

Detailed Description

Not available

Study Timeline

• Study Start: 2010-01
• Study First Submitted: 2019-06-05
• Study First Submitted QC: 2019-06-05
• Study First Posted: 2019-06-06
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-03
• Last Update Posted: 2023-07-05
• Primary Completion: 2025-12
• Study Completion: 2030-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 20000

Inclusion Criteria

• sarcoma

Read More

Exclusion Criteria

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time to next treatment (TNT)	5 years	Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.
Overall survival (OS)	5 years	Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact.

Trial Locations

Locations (3)

Centre Léon Bérard; 🇫🇷 Lyon, France

Institut Bergonié, Comprehensive Cancer Center; 🇫🇷 Bordeaux, France

Institut Gustave Roussy, Comprehensive Cancer Center; 🇫🇷 Villejuif, France